Drugs / 6-MP
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02067143 | May 2014 → Oct 2016 | precursor lymphoblastic lymphoma/leukemia | GIMEMA Foundation | Completed | Met primary |
| Phase 2 | NCT00476190 | Apr 2007 → Sep 2013 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07059156 | Jun 2025 → Jun 2027 expected | adult acute lymphoblastic leukemia | Shanxi Bethune Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01802593 | Feb 2013 → Dec 2015 | Crohn disease | Prof. Arie Levine | Terminated | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT01920737 Background | Aug 2013 → Aug 2026 overdue | leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02532738 Background | Jan 2016 → Nov 2018 | Crohn disease | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01629628 Comparator | Jul 2012 → Jul 2016 | Crohn disease | Tel-Aviv Sourasky Medical Center | Unknown | Met primary |
| Phase 3 | NCT00962767 Comparator | May 2002 → Dec 2007 | acute myeloid leukemia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02200978 Background | Sep 2011 → Oct 2021 | acute promyelocytic leukemia | South China Children's Leukemia Group | Completed | No outcome recorded |
| — | NCT07454226 Background | May 2026 → Mar 2028 expected | acute lymphoblastic leukemia, phosphohydroxylysinuria | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6-MP | “Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗9“6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.” NCT01629628 ↗ “Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks” NCT01802593 ↗ “The Drug including 6MP, AZA, infliximab and thalidomide” NCT02532738 ↗ “6-MP: 50-75 mg/m²/day fasting (7-14 days PO).” NCT07059156 ↗ “IDR + CY + ARA-C + ASP + 6MP + DXM + IT” NCT02067143 ↗ |
| Known as | 6-mercaptopurine | “We aimed to compare the rates of POR in patients treated early with prophylactic 6-mercaptopurine (6-MP) or adalimumab.” PMID 38137669 ↗ Dec 20231“Drug: 6-MP (6-Mercaptopurine)” NCT01920737 ↗ |
| Route | Oral | “Induction: Orally on days 3-43 or 33-46.” NCT00476190 ↗ |